NCT06637059Completed
Artificially Intelligent Model for Accurate Detection of HCC
Construction of an Artificially Intelligent Model for Accurate Detection of HCC by Integrating Clinical, Radiological, and Peripheral Immunological Features
Source: ClinicalTrials.gov · Last updated 15 Oct 2024
Brief summary (registry, in English)
Purpose: Integrating comprehensive information on hepatocellular carcinoma (HCC) is essential to improve its early detection. The investigators aimed to develop a model with multi-modal features (MMF) using artificial intelligence (AI) approaches to enhance the performance of HCC detection. Experimental Design: A total of 1,092 participants were enrolled from 16 centers. These participants were allocated into the training, internal validation, and external validation cohorts. Peripheral blood specimens were collected prospectively and subjected to mass cytometry analysis. Clinical and radiological data were obtained from electrical medical records. Various AI methods were employed to identify pertinent features and construct single-modal models with optimal performance. The XGBoost algorithm was utilized to amalgamate these models, integrating multi-modal information and facilitating the development of a fusion model. Model evaluation and interpretability were demonstrated using the SHapley Additive exPlanations method.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1092 (actual)
- First submitted
- 5 Oct 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- Zhejiang University
- NCT number
- NCT06637059
What you commit to
- Study type: Observational
- Participants enrolled: 1092
- From 1 Jan 2024 to the primary completion date, 1 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who had undergone previous treatment for HCC or benign liver diseases,
- had taken medications affecting the hematological system within 2 weeks
- those who had received a blood transfusion within 6 months
Who the study is looking for
- Benign liver diseases, including but not limited to, hemangiomas, hepatic cysts, focal nodular hyperplasia, and cirrhosis
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.